Anavex Life Sciences Corp (AVXL)

[sokol]

Bio:

Thank you. You are making it easier for us to read the tea leaves. Biogen is indeed interested in Anavex’s areas of focus. I think you are on to something.

After reading your post, I went back to look at the announcement of that agreement Anavex signed with Biogen in 2016. It was a material transfer agreement with Biogen in September 2016 to conduct tests with AVXL 2-73 in relation to demyelinating diseases. The studies were to ”...examine the therapeutic role ANAVEX 2-73 may play in permitting remyelination in the brain..” https://www.anavex.com/anavex-compound-to-be-tested-in-biogen-neurological-protection-model/

How does one study the role our drug plays ”in permitting remyelination in the brain” without performing work that may relate to other CNS diseases? The answer is that this study cannot be conducted without knowledge and understanding of how AVXL 2-73 effects the Central nervous system. Therefore, the study must relate to the role AVXL 2-73 plays in treating CNS diseases in general. See this previous post: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143320176

Thus, Biogen undoubtedly has and is studying AVXL 2-73 and how it may treat any CNS disease.